MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
MiNK Therapeutics, a clinical-stage biopharmaceutical company specializing in allogeneic invariant natural killer T cell therapies, announced its 2026 Annual Shareholders Meeting will be held virtually on June 17, 2026. The meeting provides an opportunity for shareholders to engage with company leadership and receive updates on the development of i…